Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide X is CR2, N or N-oxide Y is CR3, N or N-oxide Z is CR4, N or N-oxide and at least one of W, X, Y, and Z is N or N-oxide and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.